Robert T Chen

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment

P. Folegatti, D. Jenkin, Susan J. Morris, 2022, Vaccine.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.

A. Dimitrov, J. Eldridge, M. Egan, 2021, Vaccine.

Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services

B. Carleton, S. Kochhar, O. Levy, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

S. Kochhar, K. Sumathy, J. Excler, 2022, Vaccine.

Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12–13 February 2020

R. Karron, N. Lurie, M. Saville, 2021, Vaccine.

Evolution of the COVID-19 vaccine development landscape

J. Cramer, T. Le, Robert T Chen, 2020, Nature Reviews Drug Discovery.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine

M. Gurwith, E. R. Smith, Robert T Chen, 2023, Vaccine.